Advertisement
Conference Call Information
Sunesis' management will host a conference call to review the results ofthe quarter and to provide an update on the company's business on Thursday,November 1, 2007 at 10:30 am EDT. Individual and institutional investors canaccess the call via (888) 297-0358 (U.S. and Canada) or (719) 325-2215(international). To access the live audio webcast or the subsequent archivedrecording, visit the "Investors and Media -- Calendar of Events" section ofthe Sunesis website at http://www.sunesis.com. Please log on to Sunesis'website several minutes prior to the start of the presentation to ensureadequate time for any software download that may be necessary.
Advertisement
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on thediscovery, development and commercialization of novel small moleculetherapeutics for oncology and other serious diseases. Sunesis has built abroad product candidate portfolio through internal discovery and in-licensingof novel cancer therapeutics. Sunesis is advancing its product candidatesthrough in-house research and development efforts and strategic collaborationswith leading pharmaceutical and biopharmaceutical companies. For additionalinformation on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
Safe Harbor Statement
This press release contains forward-looking statements including withoutlimitation statements related to the potential efficacy of SNS-595, SNS-032and SNS-314, planned additional clinical testing and development efforts andthe anticipated timing of the commencement and completion of clinical trialsand the announcement of clinical results. Words such as "support," "will,""possible," "optimistic," "expects" and similar expressions are intended toidentify forward-looking statements. These forward-looking statements arebased upon Sunesis' current expectations. Forward-looking statements involverisks and uncertainties. Sunesis' actual results and the timing of eventscould differ materially from those anticipated in such forward-lookingstatements as a result of these risks and uncertainties, which include,without limitation, the risk that Sunesis' drug discovery and developmentactivities could be halted significantly or delayed for various reasons, therisk that Sunesis' clinical trials for SNS-595, SNS-032 and SNS-314 may notdemonstrate safety or efficacy or lead to regulatory approval, risks relatedto the conduct of Sunesis' clinical trials and manufacturing of SNS-595,SNS-032 and SNS-314 and risks related to Sunesis' need for additional funding.These and other risk factors are discussed under "Risk Factors" and elsewherein Sunesis' annual report on Form 10-K for the year ended December 31, 2006and other filings with the Securities and Exchange Commission. Sunesisexpressly disclaims any obligation or undertaking to release publicly anyupdates or revisions to any forward-looking statements contained herein toreflect any change in the company's expectations with regard thereto or anychange in events, conditions or circumstances on which any such statements arebased.Recent Highlights SNS-595 -- In October, at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Sunesis presented preliminary results from the company's ongoing Phase 2 clinic
